Moreover, given no heterogeneous treatment effects found by age, gender, or diabetes severity for GLP-1RAs versus insulin in our previous analyses [6] and limited study subjects with different patient characteristics in the present study, performing the cost-effectiveness analysis stratified by different patient demographic or clinical characteristics would be infeasible
More research is needed, but its something doctors keep in mind when planning long-term treatment
So its interesting because it all stems from kind of a flood of anecdotal reports from people just saying, like, You know, Im taking these drugs, and Im noticing not only are some of myyou know, like, my satiety levels are different
There are even reports of a reduction in appetite at higher doses
References: [1] Orrick, Herrington & Sutcliffe LLP